{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:11Z","timestamp":1786994411448,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T00:00:00Z","timestamp":1697932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.msard.2023.105100","type":"journal-article","created":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T09:51:56Z","timestamp":1697968316000},"page":"105100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6531-6979","authenticated-orcid":false,"given":"Cato E.A.","family":"Corsten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone A.","family":"Huygens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs M.","family":"Versteegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrijs H.A.","family":"Wokke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8174-2898","authenticated-orcid":false,"given":"Ide","family":"Smets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Smolders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.105100_bib0001","unstructured":"Actelion. Oral ponesimod versus teriflunomide in relapsing multiple sclerosis, (2015)."},{"key":"10.1016\/j.msard.2023.105100_bib0002","article-title":"The impact of sphinogosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination","author":"Baker","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105100_bib0003","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40120-019-00160-9","article-title":"Fingolimod rebound: a review of the clinical experience and management considerations","volume":"8","author":"Barry","year":"2019","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2023.105100_bib0004","doi-asserted-by":"crossref","first-page":"e1810","DOI":"10.1212\/WNL.0000000000200150","article-title":"The economic burden of multiple sclerosis in the United States: estimate of direct and indirect costs","volume":"98","author":"Bebo","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.105100_bib0005","first-page":"12","article-title":"Pregnancy management in multiple sclerosis and other demyelinating diseases","volume":"28","author":"Bove","year":"2022","journal-title":"Continuum"},{"key":"10.1016\/j.msard.2023.105100_bib0006","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ana.25323","article-title":"Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas","volume":"84","author":"Bovis","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.105100_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/cells11132058","article-title":"Sphingosine-1-phosphate (S1P) and S1P signaling pathway modulators, from current insights to future perspectives","volume":"11","author":"Bravo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.msard.2023.105100_bib0008","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.105100_bib0009","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.105100_bib0010","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ana.24217","article-title":"Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide","volume":"76","author":"Colombo","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.105100_bib0011","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.105100_bib0012","first-page":"1025","article-title":"Treatment of Multiple Sclerosis","volume":"28","author":"Cross","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.msard.2023.105100_bib0013","series-title":"Network Meta-Analysis for Decision-Making","author":"Dias","year":"2018"},{"key":"10.1016\/j.msard.2023.105100_bib0014","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-16-0527","article-title":"Cost-utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves' disease","volume":"175","author":"Donovan","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.msard.2023.105100_bib0015","unstructured":"Farmacotherapeutisch Rapport Natalizumab (Tysabri\u00ae) Bij 'zeer actieve Relapsing Remitting Multiple Scleroise (RRMS) met een hoge ziekteactiviteit ondanks behandeling met interferon b\u00e8ta'. 2014."},{"key":"10.1016\/j.msard.2023.105100_bib0016","unstructured":"Guideline for Conducting Economic Evaluations in Healthcare [in Dutch: richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg]. 2016."},{"key":"10.1016\/j.msard.2023.105100_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420987031","article-title":"Health economics of disease-modifying therapy for multiple sclerosis in the United States","volume":"14","author":"Hartung","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.105100_bib0018","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.105100_bib0019","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.jval.2021.05.020","article-title":"Modeling the cost-utility of treatment sequences for multiple sclerosis","volume":"24","author":"Huygens","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2023.105100_bib0020","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1523\/JNEUROSCI.4645-04.2005","article-title":"Edg8\/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival","volume":"25","author":"Jaillard","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.msard.2023.105100_bib0021","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.105100_bib0022","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.105100_bib0023","article-title":"Direct health care costs associated with multiple sclerosis: a population-based cohort study from 2001 to 2020 in British Columbia, Canada","author":"Khakban","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.105100_bib0024","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.23938","article-title":"Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis","volume":"73","author":"Khan","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.105100_bib0025","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/1352458517694432","article-title":"New insights into the burden and costs of multiple sclerosis in Europe","volume":"23","author":"Kobelt","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105100_bib0026","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00415-019-09395-w","article-title":"Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"267","author":"Li","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.105100_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102826","article-title":"Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"20","author":"Liu","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2023.105100_bib0028","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.105100_bib0029","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.msard.2018.12.040","article-title":"Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis","volume":"29","author":"McCool","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105100_bib0030","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.105100_bib0031","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","article-title":"The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK","volume":"10","author":"Orme","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2023.105100_bib0032","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0016","article-title":"Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis","volume":"12","author":"Samjoo","year":"2023","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.msard.2023.105100_bib0033","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/cer-2020-0122","article-title":"Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis","volume":"9","author":"Samjoo","year":"2020","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.msard.2023.105100_bib0034","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/03007995.2017.1407303","article-title":"Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis","volume":"34","author":"Siddiqui","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.msard.2023.105100_bib0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1352458517708663","article-title":"New insights into the burden and costs of multiple sclerosis in Europe: results for the Netherlands","volume":"23","author":"Uitdehaag","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105100_bib0036","article-title":"The impact of patent expiry on drug prices: insights from the Dutch market","volume":"9","author":"van der Schans","year":"2020","journal-title":"J. Mark. Access. Health Policy"},{"key":"10.1016\/j.msard.2023.105100_bib0037","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jval.2021.11.1363","article-title":"Effectiveness and cost-effectiveness of 360 disease-modifying treatment escalation sequences in multiple sclerosis","volume":"25","author":"Versteegh","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2023.105100_bib0038","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1002\/sim.8668","article-title":"Exploiting relationships between outcomes in Bayesian multivariate network meta-analysis with an application to relapsing-remitting multiple sclerosis","author":"Waddingham","year":"2020","journal-title":"Stat. Med."},{"key":"10.1016\/j.msard.2023.105100_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172753","article-title":"Affordability of medicines in the European Union","volume":"12","author":"Zaprutko","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2023.105100_bib0040","unstructured":"Zorginstituut Nederland. Kosteneffectiviteit in de praktijk. 2015."},{"key":"10.1016\/j.msard.2023.105100_bib0041","unstructured":"Zorginstituut Nederland. Farmacotherapeutisch Kompas, https:\/\/www.farmacotherapeutischkompas.nl\/ (2022, accessed 07-07-2022)."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823006016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823006016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T21:22:43Z","timestamp":1724880163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823006016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":41,"alternative-id":["S2211034823006016"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105100","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.12.23.22283885","asserted-by":"object"}]},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105100"}}